Skip to content

PHARMACENTRE: what changed

BE 0431.307.134NACE 47.730, Retail sale of pharmaceutical productsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€56,429
2024 · €54,793+€1,636
Equity
€78,845
2024 · €77,417+€1,429
Cash
€37,902
2024 · €140,816-€102,913
Balance sheet total
€138,900
2024 · €141,827-€2,926

Largest movements

2024 to 2025
Assets
  • Cash -€102,913

    down €102,913 (-73.1%), from €140,816 to €37,902

    mainly Receivables within one year (-€99,987) and Contributions, distributions and other (-€55,000)

  • Receivables within one year +€99,987

    up €99,987 (+9,890%), from €1,011 to €100,998

    of which Other amounts receivable: +€99,967

Equity and liabilities
  • Other debts -€5,000

    down €5,000 (-8.3%), from €60,000 to €55,000

  • Profit (loss) carried forward +€1,429

    up €1,429 (+15.5%), from €9,217 to €10,645

Income statement
  • Gross operating margin +€1,922

    up €1,922 (+2.6%), from €73,147 to €75,069

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 €54,793
Gross operating margin +€1,922
Other operating charges +€13
Financial income -€32
Financial charges -€167
Taxes -€100
Result 2025 €56,429
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations -€47,913
Investment €0
Financing -€55,000
Cash 2024 €140,816
Net result for the year +€56,429
Receivables within one year -€99,987
Tax, wage and social debts +€645
Other debts -€5,000
Contributions, distributions and other -€55,000
Cash 2025 €37,902
brings cash intakes cash out
Every line side by side 33 lines
Line Code 2024 2025 Change %
Total assets 20/58 €141,827 €138,900 -€2,926 -2.1%
Current assets 29/58 €141,827 €138,900 -€2,926 -2.1%
Amounts receivable within one year 40/41 €1,011 €100,998 +€99,987 +9,890%
Trade receivables 40 - €20 +€20
Other amounts receivable 41 €1,011 €100,978 +€99,967 +9,888%
Cash at bank and in hand 54/58 €140,816 €37,902 -€102,913 -73.1%
Total equity and liabilities 10/49 €141,827 €138,900 -€2,926 -2.1%
Equity 10/15 €77,417 €78,845 +€1,429 +1.8%
Contributions 10/11 €62,000 €62,000 = 0.0%
Capital 10 €62,000 €62,000 = 0.0%
Issued capital 100 €62,000 €62,000 = 0.0%
Reserves 13 €6,200 €6,200 = 0.0%
Non-distributable reserves 130/1 €6,200 €6,200 = 0.0%
Legal reserve 130 €6,200 €6,200 = 0.0%
Profit (loss) carried forward 14 €9,217 €10,645 +€1,429 +15.5%
Amounts payable 17/49 €64,410 €60,055 -€4,355 -6.8%
Amounts payable within one year 42/48 €64,410 €60,055 -€4,355 -6.8%
Taxes, remuneration and social security 45 €4,410 €5,055 +€645 +14.6%
Taxes 450/3 €4,410 €5,055 +€645 +14.6%
Other amounts payable 47/48 €60,000 €55,000 -€5,000 -8.3%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €0 - =
Other operating charges 640/8 €457 €445 -€13 -2.8%
Non-recurring operating charges 66A €0 - =
Gross operating margin 9900 €73,147 €75,069 +€1,922 +2.6%
Operating profit (loss) 9901 €72,690 €74,624 +€1,934 +2.7%
Financial income 75/76B €1,011 €979 -€32 -3.2%
Recurring financial income 75 €1,011 €979 -€32 -3.2%
Financial charges 65/66B €450 €617 +€167 +37.1%
Recurring financial charges 65 €450 €617 +€167 +37.1%
Profit (loss) for the period before taxes 9903 €73,251 €74,986 +€1,735 +2.4%
Income taxes 67/77 €18,458 €18,558 +€100 +0.5%
Profit (loss) for the period 9904 €54,793 €56,429 +€1,636 +3.0%
Profit (loss) for the period to be appropriated 9905 €54,793 €56,429 +€1,636 +3.0%

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€243,773 to €325,513

Midpoint €277,831 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years, excluding non-recurring income and charges earnings weight 50%

Worked out with Checked's starting values, not your estimate and not market data. Change the assumptions: the value follows.

Adjusted equity €78,845
Capitalised earnings €408,700 to €572,180
Indication €243,773 to €325,513

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€78,845
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€78,845

Capitalised earnings

net result for the year (9904)
2025
€56,429
2024
€54,793
2023
€34,303
excluding non-recurring income and charges
€60,433
2022
€50,042
2021
€55,756
Average result, excluding non-recurring income and charges
€57,218
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€408,700 / €476,817 / €572,180

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 16 November 2026 via checked.be.